研究发现,对于患有膝骨关节炎的肥胖病人来说,Tirzepatide比示磁素更具成本效益。 Tirzepatide is more cost-effective than semaglutide for obese patients with knee osteoarthritis, study finds.

Brigham和妇女医院的一项研究发现,对膝部骨髓炎和肥胖症患者而言,tirzepatide比 simaglutide 更具成本效益,尽管这两种药物同样能改善体重和血糖。 A study by Brigham and Women's Hospital finds tirzepatide more cost-effective than semaglutide for patients with knee osteoarthritis and obesity, though both drugs similarly improve weight and blood sugar. 使用计算机模型,研究人员比较tirzepatide、emaglutide、儿科外科和生活方式改变,终结tirzepatide可提供更好的价值。 Using a computer model, researchers compared tirzepatide, semaglutide, bariatric surgery, and lifestyle changes, concluding tirzepatide offers better value. 这些调查结果在关节炎基金会和NIH的支持下,可以指导治疗选择和覆盖面决定,强调提高生活质量和预期寿命。 The findings, supported by the Arthritis Foundation and NIH, may guide treatment choices and coverage decisions, emphasizing improved quality of life and life expectancy. 调查结果是初步的,需要进一步的研究。 Results are preliminary and require further research.